ArticleAmerican heart journal plus : cardiology research and practice2026
Long-term cardiovascular risk with cardiovascular-kidney-metabolic syndrome in U.S adults.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular-kidney-metabolic (CKM) syndrome staging helps identify cardiovascular disease (CVD) risk. Determining how predicted CVD risks vary across CKM stages in the U.S can further improve understanding of disease progression and help guide prevention strategies. Methods: We analyzed 2011-2020 NHANES data using survey-weighted quantile regression to compare total CVD risks predicted by the PREVENT equations across CKM stages. Results: Among 12,349 CVD-free adults aged 30-79 (∼122.8 million adults), median (25th - 75th) 10-year and 30-year CVD risks were 0.9% (0.5-2.1%) and 6.0% (3.3-10.1%) in Stage 0, 1.5% (0.7-3.3%) and 8.9% (4.7-14.9%) in Stage 1, 4.6% (2.0-9.2%) and 18.4% (0.4-26.3%) in Stage 2, and 23.5% (21.3-27.1%) and 51.6% (38.3-58.6%) in Stage 3 CKM, respectively. Higher CKM stage generally predicted higher CVD risks. Men had higher risks than women, while race/ethnicity differences were modest. Conclusion: CVD risks estimated by PREVENT equations increase with higher CKM stage, supporting CKM staging for risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.